ArticleFrontiers in oncology2026

Efficacy and safety of orelabrutinib plus R-CDOP as first-line therapy in diffuse large B-cell lymphoma with high-risk CNS-IPI: a prospective, multicenter, single-arm, phase II study.

Yiding Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.